Asia Deal Watch: Takeda Keeps Up Hectic Deals Pace Via Three New Alliances
Executive Summary
Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.
You may also be interested in...
J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.
Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.